Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis.

Leonard D, Svenungsson E, Dahlqvist J, Alexsson A, Ärlestig L, Taylor KE, Sandling JK, Bengtsson C, Frodlund M, Jönsen A, Eketjäll S, Jensen-Urstad K, Gunnarsson I, Sjöwall C, Bengtsson AA, Eloranta ML, Syvänen AC, Rantapää-Dahlqvist S, Criswell LA, Rönnblom L.

Ann Rheum Dis. 2018 Mar 7. pii: annrheumdis-2017-212614. doi: 10.1136/annrheumdis-2017-212614. [Epub ahead of print]


TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variant.

Thornton P, Sevalle J, Deery MJ, Fraser G, Zhou Y, Ståhl S, Franssen EH, Dodd RB, Qamar S, Gomez Perez-Nievas B, Nicol LS, Eketjäll S, Revell J, Jones C, Billinton A, St George-Hyslop PH, Chessell I, Crowther DC.

EMBO Mol Med. 2017 Oct;9(10):1366-1378. doi: 10.15252/emmm.201707673.


Determining myeloperoxidase activity and protein concentration in a single assay: Utility in biomarker and therapeutic studies.

Russell M, Prokoph N, Henderson N, Eketjäll S, Balendran CA, Michaëlsson E, Fidock M, Hughes G.

J Immunol Methods. 2017 Oct;449:76-79. doi: 10.1016/j.jim.2017.07.003. Epub 2017 Jul 13.


BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides.

Sakamoto K, Matsuki S, Matsuguma K, Yoshihara T, Uchida N, Azuma F, Russell M, Hughes G, Haeberlein SB, Alexander RC, Eketjäll S, Kugler AR.

J Clin Pharmacol. 2017 Nov;57(11):1460-1471. doi: 10.1002/jcph.950. Epub 2017 Jun 15.


AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease.

Cebers G, Alexander RC, Haeberlein SB, Han D, Goldwater R, Ereshefsky L, Olsson T, Ye N, Rosen L, Russell M, Maltby J, Eketjäll S, Kugler AR.

J Alzheimers Dis. 2017;55(3):1039-1053.


AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.

Eketjäll S, Janson J, Kaspersson K, Bogstedt A, Jeppsson F, Fälting J, Haeberlein SB, Kugler AR, Alexander RC, Cebers G.

J Alzheimers Dis. 2016;50(4):1109-23. doi: 10.3233/JAD-150834.


Modeling of age-dependent amyloid accumulation and γ-secretase inhibition of soluble and insoluble Aβ in a transgenic mouse model of amyloid deposition.

Parkinson J, Ploeger B, Appelkvist P, Bogstedt A, Dillner Bergstedt K, Eketjäll S, Visser SA.

Pharmacol Res Perspect. 2013 Dec;1(2):e00012. doi: 10.1002/prp2.12. Epub 2013 Dec 5.


Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.

Strömberg K, Eketjäll S, Georgievska B, Tunblad K, Eliason K, Olsson F, Radesäter AC, Klintenberg R, Arvidsson PI, von Berg S, Fälting J, Cowburn RF, Dabrowski M.

FEBS J. 2015 Jan;282(1):65-73. doi: 10.1111/febs.13103. Epub 2014 Nov 7.


Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.

Georgievska B, Gustavsson S, Lundkvist J, Neelissen J, Eketjäll S, Ramberg V, Bueters T, Agerman K, Juréus A, Svensson S, Berg S, Fälting J, Lendahl U.

J Neurochem. 2015 Feb;132(4):477-86. doi: 10.1111/jnc.12937. Epub 2014 Sep 18.


Population PKPD modeling of BACE1 inhibitor-induced reduction in Aβ levels in vivo and correlation to in vitro potency in primary cortical neurons from mouse and guinea pig.

Janson J, Eketjäll S, Tunblad K, Jeppsson F, Von Berg S, Niva C, Radesäter AC, Fälting J, Visser SA.

Pharm Res. 2014 Mar;31(3):670-83. doi: 10.1007/s11095-013-1189-y. Epub 2013 Oct 3.


AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice.

Eketjäll S, Janson J, Jeppsson F, Svanhagen A, Kolmodin K, Gustavsson S, Radesäter AC, Eliason K, Briem S, Appelkvist P, Niva C, Berg AL, Karlström S, Swahn BM, Fälting J.

J Neurosci. 2013 Jun 12;33(24):10075-84. doi: 10.1523/JNEUROSCI.1165-13.2013.


Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease.

Jeppsson F, Eketjäll S, Janson J, Karlström S, Gustavsson S, Olsson LL, Radesäter AC, Ploeger B, Cebers G, Kolmodin K, Swahn BM, von Berg S, Bueters T, Fälting J.

J Biol Chem. 2012 Nov 30;287(49):41245-57. doi: 10.1074/jbc.M112.409110. Epub 2012 Oct 9.


New aminoimidazoles as β-secretase (BACE-1) inhibitors showing amyloid-β (Aβ) lowering in brain.

Gravenfors Y, Viklund J, Blid J, Ginman T, Karlström S, Kihlström J, Kolmodin K, Lindström J, von Berg S, von Kieseritzky F, Bogar K, Slivo C, Swahn BM, Olsson LL, Johansson P, Eketjäll S, Fälting J, Jeppsson F, Strömberg K, Janson J, Rahm F.

J Med Chem. 2012 Nov 8;55(21):9297-311. doi: 10.1021/jm300991n. Epub 2012 Oct 3. Erratum in: J Med Chem. 2012 Nov 26;55(22):10316. Bogar, Krisztian [added].


Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.

Swahn BM, Kolmodin K, Karlström S, von Berg S, Söderman P, Holenz J, Berg S, Lindström J, Sundström M, Turek D, Kihlström J, Slivo C, Andersson L, Pyring D, Rotticci D, Ohberg L, Kers A, Bogar K, von Kieseritzky F, Bergh M, Olsson LL, Janson J, Eketjäll S, Georgievska B, Jeppsson F, Fälting J.

J Med Chem. 2012 Nov 8;55(21):9346-61. doi: 10.1021/jm3009025. Epub 2012 Sep 17.


Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase.

Scott RP, Eketjäll S, Aineskog H, Ibáñez CF.

J Biol Chem. 2005 Apr 8;280(14):13442-9. Epub 2005 Jan 27.


Recent evolutionary origin within the primate lineage of two pseudogenes with similarity to members of the transforming growth factor-beta superfamily.

Eketjäll S, Jörnvall H, Lönnerberg P, Kobayashi S, Ibáñez CF.

Cell Mol Life Sci. 2004 Feb;61(4):488-96.


Functional characterization of mutations in the GDNF gene of patients with Hirschsprung disease.

Eketjäll S, Ibáñez CF.

Hum Mol Genet. 2002 Feb 1;11(3):325-9.


Distinct structural elements in GDNF mediate binding to GFRalpha1 and activation of the GFRalpha1-c-Ret receptor complex.

Eketjäll S, Fainzilber M, Murray-Rust J, Ibáñez CF.

EMBO J. 1999 Nov 1;18(21):5901-10.


Supplemental Content

Loading ...
Support Center